# ImmuneSpec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunespec

- Industry: Biotechnology
- Headquarters: Antwerp, Belgium
- Website: www.immunespec.com/
- Total disclosed funding: $1.3M
- Latest round: Seed (Mar 23, 2023)
- Investors on record: 1

## About

Based in Antwerp, Belgium, and founded in 2023 by CEO Elise Pepermans and CSO Geert Baggerman, ImmuneSpec BV operates as a biotechnology research company that provides an advanced immune peptidomics platform for the identification of immunogenic peptides. In March 2023, ImmuneSpec BV raised EUR 1.2 million in seed funding from HERAN Partners. 

ImmuneSpec BV provides a drug development process including purification methods for generating several immunopeptides, spectrometry analysis to capture immunogenic regions, and data-analysis methodology for coverage of immunogenic regions. The company offers life science companies, biotech companies, and CROs in the development of broad-spectrum vaccines, personalized medicine, and immunotherapeutics. In addition, the firm provides an immune peptidomics platform for the identification of immunogenic peptides. 

The company plans to use the funding from March 2023 to bring this platform to market and revolutionize the development of next-generation biologicals.

## Funding rounds

- Seed, Mar 23, 2023, $1.3M — HERAN Partners

## Investors

- HERAN Partners (https://capitalatlas.ai/funds/heran-partners) — Seed